Company Announcements

Change of Auditor

Source: RNS
RNS Number : 2248G
Eco Animal Health Group PLC
14 November 2022
 

14 November 2022

ECO Animal Health Group plc

(the "Company" or the "Group") (AIM: EAH)

 

Change of Auditor

  

Following a competitive tender process overseen by the Group's Audit & Risk Committee, the Company announces the resignation of BDO LLP as auditor and the appointment, with immediate effect, of Haysmacintyre LLP as auditor for the financial year ending 31 March 2023. Haysmacintyre's re-appointment for the subsequent financial year will be subject to approval by shareholders at the next Annual General Meeting of the Company to be held in 2023.

 

The Group's Audit & Risk Committee decided to undertake a formal audit tender process following the end of the last financial period. BDO LLP has deposited with the Company a statement confirming that there are no matters to be brought to the attention of the Company's members or creditors.

 

For further information, please contact:

 

Contacts:

ECO Animal Health Group plc

David Hallas (CEO)

Christopher Wilks (CFO)

 


020 8447 8899

 

IFC Advisory

Graham Herring

Zach Cohen

 

020 3934 6630

 

Singer Capital Markets (Nominated Adviser & Joint Broker)

Mark Taylor

George Tzimas

 

020 7496 3000

Investec (Joint Broker)

Gary Clarence

Brough Ransom

Carlo Spingardi

 

020 7597 5970

Peel Hunt LLP (Joint Broker)

Dr Christopher Golden

020 7418 8900

James Steel

 

Equity Development

Hannah Crowe

Matt Evans

 020 7065 2692

 

 

 

 

About ECO Animal Health

ECO Animal Health Group plc researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new products

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
APPFZMMMMFKGZZZ